Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
E-therapeutics Plc LSE:ETX London Ordinary Share GB00B2823H99 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.75 3.57% 21.75 5,037,564 14:49:24
Bid Price Offer Price High Price Low Price Open Price
21.50 22.00 22.75 21.50 21.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.46 -2.87 -0.87 70
Last Trade Time Trade Type Trade Size Trade Price Currency
17:11:19 O 250,000 21.9999 GBX

E-therapeutics (ETX) Latest News (3)

More E-therapeutics News
E-therapeutics Takeover Rumours

E-therapeutics (ETX) Discussions and Chat

E-therapeutics Forums and Chat

Date Time Title Posts
28/5/202021:57E-Therapeutics ETX : Applying AI / ML to drug discovery & development513
06/1/202009:14ETX-Fighting MRSA & winning.1,094
27/6/201912:55ETX, The Boss & the Company2
18/5/201310:49ETX : Stocktube Vid74

Add a New Thread

E-therapeutics (ETX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2020-05-28 16:15:0022.00250,00054,999.75O
2020-05-28 16:15:0021.501,000,000215,000.00O
2020-05-28 16:15:0021.75250,00054,375.00O
2020-05-28 16:15:0021.75250,00054,375.00O
2020-05-28 16:15:0022.25250,00055,625.00O
View all E-therapeutics trades in real-time

E-therapeutics (ETX) Top Chat Posts

DateSubject
28/5/2020
09:20
E-therapeutics Daily Update: E-therapeutics Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker ETX. The last closing price for E-therapeutics was 21p.
E-therapeutics Plc has a 4 week average price of 11.38p and a 12 week average price of 5.15p.
The 1 year high share price is 22.75p while the 1 year low share price is currently 1.43p.
There are currently 322,427,853 shares in issue and the average daily traded volume is 2,065,785 shares. The market capitalisation of E-therapeutics Plc is £70,128,058.03.
11/2/2020
10:43
someuwin: SP Angel... "e-therapeutics (ETX.L): Board restructuring Share Price: 3.9p; Market Capitalisation: £10.5m * e-therapeutics, a computational drug discovery business, announced board restructuring and a £1.6m placing. * Ali Mortazavi has been appointed Executive Chairman, with the current Non-Executive Chairman, CEO and CFO departing the Company. * The Group also £1.6m placing at 3p/share with the funds to be used for general working capital purposes. The appointment of Mr Mortazavi, who was CEO of Silence Therapeutics (SLN.L), for six years, marks an opportunity to turnaround the business, which was affected last year by the Woodford overhang. The current Group strategy is to strike revenue or cash generating collaborations through its network-driven drug discovery (NDD) and Genome Associated Interaction Networks (GAINs) platforms and has collaborations with big pharma, including Novo Nordisk. Computer-based drug development is an attractive prospect for industry, as it could dramatically reduce risk, cost and time by generating data in silico rather than in the lab."
11/2/2020
10:28
matt123d: An illiquid stock where holders and directors have a massive financial incentive to get the share price higher.
11/2/2020
09:53
the stigologist: It's a great stock right now. Highly concentrated shareholder base. Mortazavi, Griffiths and Norwood together own c. 60% Shouldn't be any need for fundraising in short term. Huge amount of newsflow to come with signposting of multiple deals incoming from major pharmas / bios This Company is hugely undervalued/mispriced compared to Exscientia and BenevolentAI I'm expecting at least 10 bags from here. But potential is 100 bags. At £1 a share Mortazavi stake will be worth £50m So he's well incentivised to get the share price up
23/1/2020
09:44
the stigologist: Obviously they must be expecting share price to improve and understand they are in a land grab phase so it's 'eat or be eaten' ? I would point once again to ETX E-therapeutics Mkt Cap £10m PYC Physiomics Mkt Cap £2m which look crazily undervalued when Private UK Unicorns like Exscientia and BenevolentAI valued at $1000m+ (vs SENS at £60m Mkt with £40m cash) htTps://www.thetimes.co.uk/article/sensyne-health-on-the-acquisition-trail-to-halt-decline-in-share-price-jmfvbcw0q Sensyne Health on the acquisition trail to halt decline in share ... Sensyne Health said that it was “exploring a small number of strategic [mergers and acquisitions] opportunities that have the potential to scale our businessmore quickly to achieve a leadership position in the clinical artificial intelligence market and create value for shareholders”.
10/1/2020
12:34
the stigologist: There are some easy big selling points : - share price depressed due to Woodfund overhang - share register now super-strong (Norwood, Mortazavi) - huge optionality as evidenced by recent deals - validation ETX have from Novo Nordisk and Merck already but plenty more deals in pipeline hTtps://investegate.co.uk/frontier-ip-group--fipp-/rns/exscientia-enters-collaboration-with-bayer-ag/202001100700093680Z/
09/7/2019
19:35
paulcon1: The share price dropped 5p in 6 months with no news so there is no reason to believe the share price would have risen 5p in 6 days on no news 😵 I am a little surprised the share price is not around 4p atm but am looking it to be around 6.5 - 7.00p (natural base level) in 4-5 weeks from now (on no news) and even more on the back of a strong contract win or stellar partnership or positive drug progress report. Let's see.. GL and IMHO and DYOR
09/7/2019
17:02
pwhite73: The share price is standing at 3p and not £1.00 because retail investors have lost interest since Woodford sold out. I could ask you if the company's broker has put a valuation of 21p on the share price why is it currently sitting at 3p. This all comes back to what I said earlier it is only news that drives the share price not fundamentals. If any retail investors were genuinely interested in fundamentals they would not be investing in the AIM. 80% of investors lose money on the AIM. This figure rises to about 95% if they decide to hold long term. Don't make excuses for ETX. Whether you decide to hold for 24 hrs, 24 days, 24 weeks, 24 months or 24 years this share price will not re-rate and find its true value without positive news.
09/7/2019
14:02
pwhite73: ETX is an AIM/microcap stock. These stocks are 100% news driven not fundamentals driven. Cash balances, IPs and assets do not determine the share price. This is why when they issue bad news everything goes out the window and they can drop up to 75% in a single day. Conversely they can also multi-bag on good news in a single day. Without news ETX will continue to drop. The Woodford selling that started in early June should have sent the share price lower but it had the opposite effect. This is because it provided news on ETX and people began to look at the company once again, and many associated the fall prior to June with Woodford selling when it was not him. Now that Woodford is and no longer an ETX related news item the stock has continued on its downward slide. A few people have looked at the fundamentals again and decided it is worth a punt. This seems to have put a floor under the share price of 2.50p - 3.00p. But this is only temporary. As the subsequent months go by without further operational news the slide will restart again. ETX and ETX alone are to blame for the decimation of its share price.
09/7/2019
13:42
paulcon1: Take Mr Woodford out of it for a second, why would the ETX share price drop from 6.5p - 1.5p over the space of 6 months, when the fundamentals remain the same. - 6.5p was excessive and pumped up? - Lack of news? - £8m is the correct mkt value Or maybe the impact of a large seller/sellers on low volume over an extended period of time. For me, I'm looking forwards the share price is around 3p (£8m mkt value) and that seems remarkably low given cash balance, IP's and potential IMHO
09/7/2019
12:52
74tom: Pwhite, the share price when the first notification can through shows the impact of him selling 10m shares in such a low volume stock, see below for more detail which I posted on LSE on 26th June; “I think Woodford first lodged his sell order on ETX before the start of 2019 - on 1st January the share price was 6.35 Volume during January was a grand total of 197k shares, yet the price ended the month at 5.25 In Feb there were 555k shares traded with the price falling to 4.8 There was a 5m sell on 20th March that coincided with a 15m volume day and a fall down to 2.8 - so the first 5m of Woodford clearing. From there until the end of April there was just 3m volume and the price stayed at 3p ish May saw another 3m volume with the price falling to 2p, finally seeing the the first Woodford notification on 3rd June confirming that he’d sold 10m shares and explaining the fall. Since then the price has fallen further before finally attracting widespread attention at 1.6p, now we have had 69m shares traded in 4 days - more than in the previous 249 trading days combined (and that includes 30m trades on 5/12 when the Novo agreement was announced, and the share price remained stuck at 6.63p). With such a historically low volume of trades (you can download the daily data from the investors page of the ETX site), it’s no wonder that a 10m sell from Woodford decimated the price! The recent volume has meant that PI’s have actually dug into ETX and discovered a company in better shape than most AIM pharmas.”
E-therapeutics share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
ETX
E-therapeu..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200529 04:19:23